Jump to content

Acromegaly

From Wikipedia, the free encyclopedia
(Redirected from Acromegalia)
This article is about the disease in humans. For the disease in animals, see Hypersomatotropism (veterinary).

Acromegaly
Lower jaw showing the classic spacing of teeth due to acromegaly.
Pronunciation
SpecialtyEndocrinology
SymptomsEnlargement of the hands, feet, forehead, jaw, and nose, thicker skin, deepening of the voice[3]
ComplicationsType 2 diabetes, sleep apnea, high blood pressure,[3] high cholesterol, heart problems, particularly enlargement of the heart (cardiomegaly), osteoarthritis, spinal cord compression or fractures, increased risk of cancerous tumors, precancerous growths (polyps) on the lining of the colon.[4]
Usual onsetMiddle age[3]
CausesExcess growth hormone (hypersomatotropism)[3]
Diagnostic methodBlood tests, medical imaging[3]
Differential diagnosisPachydermoperiostosis[5]
TreatmentSurgery, medications, radiation therapy[3]
MedicationSomatostatin analogue, GH receptor antagonist[3]
PrognosisUsually normal (with treatment), 10 year shorter life expectancy (no treatment)[6]
Frequency3 per 50,000 people[3]

Acromegaly is a disorder that results in excess growth of certain parts of the human body. It is caused by excess growth hormone (GH) after the growth plates have closed. The initial symptom is typically enlargement of the hands and feet.[3] There may also be an enlargement of the forehead, jaw, and nose. Other symptoms may include joint pain, thicker skin, deepening of the voice, headaches, and problems with vision.[3] Complications of the disease may include type 2 diabetes, sleep apnea, and high blood pressure.[3]

Cause and diagnosis

[edit]

Acromegaly is usually caused by the pituitary gland producing excess growth hormone. In more than 95% of cases, the excess production is due to a benign tumor, known as a pituitary adenoma. The condition is not inherited. Acromegaly is rarely due to a tumor in another part of the body. Diagnosis is by measuring growth hormone after a person has consumed a glucose solution, or by measuring insulin-like growth factor I in the blood. After diagnosis, medical imaging of the pituitary is carried out to determine if an adenoma is present. If excess growth hormone is produced during childhood, the result is the condition gigantism rather than acromegaly, and it is characterized by excessive height.[3]

Treatment

[edit]

Treatment options include surgery to remove the tumor, medications, and radiation therapy. Surgery is usually the preferred treatment; the smaller the tumor, the more likely surgery will be curative. If surgery is contraindicated or not curative, somatostatin analogues or GH receptor antagonists may be used. Radiation therapy may be used if neither surgery nor medications are completely effective.[3] Without treatment, life expectancy is reduced by 10 years; with treatment, life expectancy is not reduced.[6]

Epidemiology, history, and culture

[edit]

Acromegaly affects about 3 per 50,000 people. It is most commonly diagnosed in middle age.[3] Males and females are affected with equal frequency.[7] It was first described in the medical literature by Nicolas Saucerotte in 1772.[8][9] The term is from the Greek ἄκρον (akron) meaning "extremity", and μέγα (mega) meaning "large".[3]

Signs and symptoms

[edit]
Compared with the hand of an unaffected person (left), the hand of a person with acromegaly (right) is enlarged, with fingers that are widened, thickened and stubby, and with thicker soft tissue
Mandibular overgrowth leads to prognathism, maxillary widening, teeth spacing and malocclusion
Brow ridge and forehead protrusion remaining after tumor removal and tissue swelling eliminated

Features that may result from a high level of GH or expanding tumor include:[citation needed]

Complications

[edit]

Causes

[edit]

Pituitary adenoma

[edit]

About 98% of cases of acromegaly are due to the overproduction of growth hormone by a benign tumor of the pituitary gland called an adenoma.[17] These tumors produce excessive growth hormone and compress surrounding brain tissues as they grow larger. In some cases, they may compress the optic nerves. Expansion of the tumor may cause headaches and visual disturbances. In addition, compression of the surrounding normal pituitary tissue can alter the production of other hormones, leading to changes in menstruation and breast discharge in women and impotence in men because of reduced testosterone production.[18]

A marked variation in rates of GH production and the aggressiveness of the tumor occurs. Some adenomas grow slowly and symptoms of GH excess are often not noticed for many years. Other adenomas grow rapidly and invade surrounding brain areas or the sinuses, which are located near the pituitary. In general, younger people tend to have more aggressive tumors.[19]

Most pituitary tumors arise spontaneously and are not genetically inherited. Many pituitary tumors arise from a genetic alteration in a single pituitary cell that leads to increased cell division and tumor formation. This genetic change, or mutation, is not present at birth but is acquired during life. The mutation occurs in a gene that regulates the transmission of chemical signals within pituitary cells; it permanently switches on the signal that tells the cell to divide and secrete growth hormones. The events within the cell that cause disordered pituitary cell growth and GH oversecretion currently are the subject of intensive research.[19]

Pituitary adenomas and diffuse somatomammotroph hyperplasia may result from somatic mutations activating GNAS, which may be acquired or associated with McCune–Albright syndrome.[20][21]

Other tumors

[edit]

In a few people, acromegaly is caused not by pituitary tumors, but by tumors of the pancreas, lungs, and adrenal glands. These tumors also lead to an excess of GH, either because they produce GH themselves or, more frequently, because they produce GHRH (growth hormone-releasing hormone), the hormone that stimulates the pituitary to make GH. In these people, the excess GHRH can be measured in the blood and establishes that the cause of the acromegaly is not due to a pituitary defect. When these nonpituitary tumors are surgically removed, GH levels fall and the symptoms of acromegaly improve.[citation needed]

In people with GHRH-producing, non-pituitary tumors, the pituitary still may be enlarged and may be mistaken for a tumor. Therefore, it is important that physicians carefully analyze all "pituitary tumors" removed from people with acromegaly to not overlook the possibility that a tumor elsewhere in the body is causing the disorder.[citation needed]

Diagnosis

[edit]
Frequent serum GH measurements in normal subjects (left panel) demonstrate that GH can fluctuate between undetectable levels most of the time interspersed with peaks of up to 30 μg/L (90 mIU/L); in acromegaly (right panel) GH hypersecretion is continuous with no undetectable levels.

If acromegaly is suspected, medical laboratory investigations followed by medical imaging, if the lab tests are positive, confirm or rule out the presence of this condition.[citation needed]

IGF1 provides the most sensitive lab test for the diagnosis of acromegaly, and a GH suppression test following an oral glucose load, which is a very specific lab test, will confirm the diagnosis following a positive screening test for IGF1. A single value of the GH is not useful in view of its pulsatility (levels in the blood vary greatly even in healthy individuals).

Magnetic resonance image of a pituitary macroadenoma that caused acromegaly with compression of the optic chiasm

GH levels taken 2 hours after a 75- or 100-gram glucose tolerance test are helpful in the diagnosis: GH levels are suppressed below 1 μg/L in normal people, and levels higher than this cutoff are confirmatory of acromegaly.[citation needed]

Other pituitary hormones must be assessed to address the secretory effects of the tumor, as well as the mass effect of the tumor on the normal pituitary gland. They include thyroid stimulating hormone (TSH), gonadotropic hormones (FSH, LH), adrenocorticotropic hormone, and prolactin.[citation needed]

An MRI of the brain focusing on the sella turcica after gadolinium administration allows for clear delineation of the pituitary and the hypothalamus and the location of the tumor. A number of other overgrowth syndromes can result in similar problems.[citation needed]

Differential diagnosis

[edit]

Pseudoacromegaly is a condition with the usual acromegaloid features but without an increase in growth hormone and IGF-1. It is frequently associated with insulin resistance.[22] Cases have been reported due to minoxidil at an unusually high dose.[23] It can also be caused by a selective post-receptor defect of insulin signalling, leading to the impairment of metabolic, but preservation of mitogenic, signaling.[24]

Treatment

[edit]
Site of action of the different therapeutic tools in acromegaly. Surgery, radiotherapy, somatostatin analogues and dopamine agonists act at the level of the pituitary adenoma, while GH receptor antagonists act in the periphery by blocking the growth hormone receptor and thus impairing the effects of GH on the different tissues.

The goals of treatment are to reduce GH production to normal levels thereby reversing or ameliorating the signs and symptoms of acromegaly, to relieve the pressure that the growing pituitary tumor exerts on the surrounding brain areas, and to preserve normal pituitary function. Currently, treatment options include surgical removal of the tumor, drug therapy, and radiation therapy of the pituitary.[citation needed]

Medications

[edit]

Somatostatin analogues

[edit]

The primary current medical treatment of acromegaly is to use somatostatin analogues – octreotide (Sandostatin) or lanreotide (Somatuline). These somatostatin analogues are synthetic forms of a brain hormone, somatostatin, which stops GH production. The long-acting forms of these drugs must be injected every 2 to 4 weeks for effective treatment. Most people with acromegaly respond to this medication. In many people with acromegaly, GH levels fall within one hour and headaches improve within minutes after the injection. Octreotide and lanreotide are effective for long-term treatment. Octreotide and lanreotide have also been used successfully to treat people with acromegaly caused by non-pituitary tumors.[citation needed]

Somatostatin analogues are also sometimes used to shrink large tumors before surgery.[25]

Because octreotide inhibits gastrointestinal and pancreatic function, long-term use causes digestive problems such as loose stools, nausea, and gas in one-third of people. In addition, approximately 25 percent of people with acromegaly develop gallstones, which are usually asymptomatic.[26] In some cases, octreotide treatment can cause diabetes due to the fact that somatostatin and its analogues can inhibit the release of insulin.[citation needed] With an aggressive adenoma that is not able to be operated on, there may be a resistance to octreotide in which case a second-generation SSA, pasireotide, may be used for tumor control. However, insulin and glucose levels should be carefully monitored as pasireotide has been associated with hyperglycemia by reducing insulin secretion.[27]

Dopamine agonists

[edit]

For those who are unresponsive to somatostatin analogues, or for whom they are otherwise contraindicated, it is possible to treat using one of the dopamine agonists, bromocriptine, or cabergoline. As tablets rather than injections, they cost considerably less. These drugs can also be used as an adjunct to somatostatin analogue therapy. They are most effective in those whose pituitary tumours also secrete prolactin. Side effects of these dopamine agonists include gastrointestinal upset, nausea, vomiting, light-headedness when standing, and nasal congestion. These side effects can be reduced or eliminated if medication is started at a very low dose at bedtime, taken with food, and gradually increased to the full therapeutic dose. Bromocriptine lowers GH and IGF-1 levels and reduces tumor size in fewer than half of people with acromegaly. Some people report improvement in their symptoms although their GH and IGF-1 levels still are elevated.[citation needed]

Growth hormone receptor antagonists

[edit]

The latest development in the medical treatment of acromegaly is the use of growth hormone receptor antagonists. The only available member of this family is pegvisomant (Somavert). By blocking the action of the endogenous growth hormone molecules, this compound is able to control the disease activity of acromegaly in virtually everyone with acromegaly. Pegvisomant has to be administered subcutaneously by daily injections. Combinations of long-acting somatostatin analogues and weekly injections of pegvisomant seem to be equally effective as daily injections of pegvisomant.[citation needed]

Surgery

[edit]

Surgical removal of the pituitary tumor is usually effective in lowering growth hormone levels. Two surgical procedures are available for use. The first is endonasal transsphenoidal surgery, which involves the surgeon reaching the pituitary through an incision in the nasal cavity wall. The wall is reached by passing through the nostrils with microsurgical instruments. The second method is transsphenoidal surgery during which an incision is made into the gum beneath the upper lip. Further incisions are made to cut through the septum to reach the nasal cavity, where the pituitary is located. Endonasal transsphenoidal surgery is a less invasive procedure with a shorter recovery time than the older method of transsphenoidal surgery, and the likelihood of removing the entire tumor is greater with reduced side effects. Consequently, endonasal transsphenoidal surgery is the more common surgical choice.[citation needed]

These procedures normally relieve the pressure on the surrounding brain regions and lead to a lowering of GH levels. Surgery is most successful in people with blood GH levels below 40 ng/ml before the operation and with pituitary tumors no larger than 10 mm in diameter. Success depends on the skill and experience of the surgeon. The success rate also depends on what level of GH is defined as a cure. The best measure of surgical success is the normalization of GH and IGF-1 levels. Ideally, GH should be less than 2 ng/ml after an oral glucose load. A review of GH levels in 1,360 people worldwide immediately after surgery revealed that 60% had random GH levels below 5 ng/ml. Complications of surgery may include cerebrospinal fluid leaks, meningitis, or damage to the surrounding normal pituitary tissue, requiring lifelong pituitary hormone replacement.[citation needed]

Even when surgery is successful and hormone levels return to normal, people must be carefully monitored for years for possible recurrence. More commonly, hormone levels may improve, but not return completely to normal. These people may then require additional treatment, usually with medications.[citation needed]

Radiation therapy

[edit]

Radiation therapy has been used both as a primary treatment and combined with surgery or drugs. It is usually reserved for people who have tumours remaining after surgery. These people often also receive medication to lower GH levels. Radiation therapy is given in divided doses over four to six weeks. This treatment lowers GH levels by about 50 percent over 2 to 5 years. People monitored for more than 5 years show significant further improvement. Radiation therapy causes a gradual loss of production of other pituitary hormones with time. Loss of vision and brain injury, which have been reported, are very rare complications of radiation treatments.[citation needed]

Selection of treatment

[edit]

The initial treatment chosen should be individualized depending on the person's characteristics, such as age and tumor size. If the tumor has not yet invaded surrounding brain tissues, removal of the pituitary adenoma by an experienced neurosurgeon is usually the first choice. After surgery, a person must be monitored long-term for increasing GH levels.[citation needed]

If surgery does not normalize hormone levels or a relapse occurs, a doctor will usually begin additional drug therapy. The current first choice is generally octreotide or lanreotide; however, bromocriptine and cabergoline are both cheaper and easier to administer. With all of these medications, long-term therapy is necessary, because their withdrawal can lead to rising GH levels and tumor re-expansion. [citation needed]

Radiation therapy is generally used for people whose tumors are not completely removed by surgery, for people who are not good candidates for surgery because of other health problems, and for people who do not respond adequately to surgery and medication.[citation needed]

Prognosis

[edit]

Life expectancy of people with acromegaly is dependent on how early the disease is detected.[28] Life expectancy after the successful treatment of early disease is equal to that of the general population.[29] Acromegaly can often go on for years before diagnosis, resulting in poorer outcome, and it is suggested that the better the growth hormone is controlled, the better the outcome.[28] Upon successful surgical treatment, headaches and visual symptoms tend to resolve.[12] One exception is sleep apnea, which is present in around 70% of cases but does not tend to resolve with successful treatment of growth hormone level.[11] While hypertension is a complication of 40% of cases, it typically responds well to regular regimens of blood pressure medication.[11] Diabetes that occurs with acromegaly is treated with the typical medications, but successful lowering of growth hormone levels often alleviates symptoms of diabetes.[11] Hypogonadism without gonad destruction is reversible with treatment.[11] Acromegaly is associated with a slightly elevated risk of cancer.[30]

Notable people

[edit]

See also

[edit]

References

[edit]
  1. ^ "acromegaly". Lexico UK English Dictionary. Oxford University Press. Archived from the original on 22 March 2020.
  2. ^ "acromegaly". Merriam-Webster.com Dictionary. Merriam-Webster. Retrieved 20 January 2021.
  3. ^ a b c d e f g h i j k l m n o "Acromegaly". NIDDK. April 2012. Archived from the original on 27 August 2016. Retrieved 20 August 2016.
  4. ^ "Acromegaly". mayoclinic.org.
  5. ^ Guglielmi G, Van Kuijk C (2001). Fundamentals of Hand and Wrist Imaging. Springer Science & Business Media. p. 205. ISBN 9783540678540. Archived from the original on 8 September 2017.
  6. ^ a b Ho K (2011). Growth Hormone Related Diseases and Therapy: A Molecular and Physiological Perspective for the Clinician. Springer Science & Business Media. p. 400. ISBN 9781607613176. Archived from the original on 25 August 2016.
  7. ^ Pack AI (2016). Sleep Apnea: Pathogenesis, Diagnosis and Treatment (2 ed.). CRC Press. p. 291. ISBN 9781420020885. Archived from the original on 25 August 2016.
  8. ^ Pearce JM (2003). Fragments of Neurological History. World Scientific. p. 501. ISBN 9781783261109. Archived from the original on 25 August 2016.
  9. ^ Pearce JM (September 2006). "Nicolas Saucerotte: Acromegaly before Pierre Marie". Journal of the History of the Neurosciences. 15 (3): 269–75. doi:10.1080/09647040500471764. PMID 16887764. S2CID 22801883.
  10. ^ James W, Berger T, Elston D (2005). Andrews' Diseases of the Skin: Clinical Dermatology (10th ed.). Saunders. ISBN 0-7216-2921-0.
  11. ^ a b c d e f g h i Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, et al. (September 2013). "A consensus on the diagnosis and treatment of acromegaly complications". Pituitary. 16 (3): 294–302. doi:10.1007/s11102-012-0420-x. PMC 3730092. PMID 22903574.
  12. ^ a b Laws ER (March 2008). "Surgery for acromegaly: evolution of the techniques and outcomes". Reviews in Endocrine & Metabolic Disorders. 9 (1): 67–70. doi:10.1007/s11154-007-9064-y. PMID 18228147. S2CID 1365262.
  13. ^ Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, et al. (June 2011). "Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry". European Journal of Endocrinology. 164 (6): 877–84. doi:10.1530/EJE-10-1050. PMID 21464140.
  14. ^ Renehan AG, O'Connell J, O'Halloran D, Shanahan F, Potten CS, O'Dwyer ST, Shalet SM (2003). "Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications". Hormone and Metabolic Research. 35 (11–12): 712–25. doi:10.1055/s-2004-814150. PMID 14710350. S2CID 260166366.
  15. ^ Wolinski K, Czarnywojtek A, Ruchala M (14 February 2014). "Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly—meta-analysis and systematic review". PLOS ONE. 9 (2): e88787. Bibcode:2014PLoSO...988787W. doi:10.1371/journal.pone.0088787. PMC 3925168. PMID 24551163.
  16. ^ Melmed S, Jackson I, Kleinberg D, Klibanski A (August 1998). "Current treatment guidelines for acromegaly". The Journal of Clinical Endocrinology and Metabolism. 83 (8): 2646–52. doi:10.1210/jcem.83.8.4995. PMID 9709926.
  17. ^ Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J (8 April 2015). Harrison's Principles of Internal Medicine (19th ed.). McGraw Hill. pp. 2269–2271. ISBN 978-0071802154.
  18. ^ Ganapathy, M. K.; Tadi, P. (2022). "Anatomy, Head and Neck, Pituitary Gland". National Center for Biotechnology Information, U.S. National Library of Medicine. PMID 31855373. Retrieved 27 June 2021.
  19. ^ a b Ganapathy, M. K.; Tadi, P. (2022). "Anatomy, Head and Neck, Pituitary Gland". National Center for Biotechnology Information, U.S. National Library of Medicine. PMID 31855373. Retrieved 27 June 2021.
  20. ^ Vortmeyer AO, Gläsker S, Mehta GU, Abu-Asab MS, Smith JH, Zhuang Z, et al. (July 2012). "Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune–Albright syndrome". The Journal of Clinical Endocrinology and Metabolism. 97 (7): 2404–13. doi:10.1210/jc.2012-1274. PMC 3791436. PMID 22564667.
  21. ^ Salenave S, Boyce AM, Collins MT, Chanson P (June 2014). "Acromegaly and McCune–Albright syndrome". The Journal of Clinical Endocrinology and Metabolism. 99 (6): 1955–69. doi:10.1210/jc.2013-3826. PMC 4037730. PMID 24517150.
  22. ^ Yaqub, Abid; Yaqub, Nadia (1 September 2008). "Insulin-mediated pseudoacromegaly: a case report and review of the literature". West Virginia Medical Journal. 104 (5): 12–16. PMID 18846753. Gale A201087184.
  23. ^ Nguyen KH, Marks JG (June 2003). "Pseudoacromegaly induced by the long-term use of minoxidil". Journal of the American Academy of Dermatology. 48 (6): 962–5. doi:10.1067/mjd.2003.325. PMID 12789195.
  24. ^ Sam AH, Tan T, Meeran K (2011). "Insulin-mediated 'pseudoacromegaly'". Hormones. 10 (2): 156–61. doi:10.14310/horm.2002.1306. PMID 21724541.
  25. ^ "Acromegaly and Gigantism". The Lecturio Medical Concept Library. Retrieved 27 June 2021.
  26. ^ "Octreotide Side Effects". Archived from the original on 22 April 2016. Retrieved 24 July 2019.
  27. ^ Yamamoto, Reina; Robert Shima, Kosuke; Igawa, Hirobumi; Kaikoi, Yuka; Sasagawa, Yasuo; Hayashi, Yasuhiko; Inoshita, Naoko; Fukuoka, Hidenori; Takahashi, Yutaka; Takamura, Toshinari (2018). "Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly". Endocrine Journal. 65 (10): 1061–1067. doi:10.1507/endocrj.ej17-0487. ISSN 0918-8959. PMID 30078825.
  28. ^ a b Lugo G, Pena L, Cordido F (2012). "Clinical manifestations and diagnosis of acromegaly". International Journal of Endocrinology. 2012: 540398. doi:10.1155/2012/540398. PMC 3296170. PMID 22518126.
  29. ^ Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JA, et al. (September 2018). "A Consensus Statement on acromegaly therapeutic outcomes". Nature Reviews. Endocrinology. 14 (9): 552–561. doi:10.1038/s41574-018-0058-5. PMC 7136157. PMID 30050156.
  30. ^ Dal, Jakob; Leisner, Michelle Z; Hermansen, Kasper; Farkas, Dóra Körmendiné; Bengtsen, Mads; Kistorp, Caroline; Nielsen, Eigil H; Andersen, Marianne; Feldt-Rasmussen, Ulla; Dekkers, Olaf M; Sørensen, Henrik Toft; Jørgensen, Jens Otto Lunde (1 June 2018). "Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature". The Journal of Clinical Endocrinology & Metabolism. 103 (6): 2182–2188. doi:10.1210/jc.2017-02457. PMID 29590449.
  31. ^ Times Staff And Wire Reports (5 December 2008). "Paul Benedict dies at 70; actor from 'The Jeffersons' and 'Sesame Street'". Los Angeles Times. Archived from the original on 26 August 2016.
  32. ^ Duryea B (27 June 1999). "Floridian: In love with a monster". St Petersburg Times. Archived from the original on 8 June 2016.
  33. ^ Dagan C (8 July 2015). "Irwin Keyes, Horror Movie Character Actor, Dies at 63". Variety. Archived from the original on 29 May 2016.
  34. ^ "Richard "Jaws" Kiel, Famed Bond Movie Villain, Raises Awareness Oflife-Threatening Hormone Disorder". PR Newswire. Archived from the original on 10 July 2009. Retrieved 26 July 2010.
  35. ^ Stampede P. "Neil McCarthy". The Avengers Forever. Retrieved 29 January 2014.
  36. ^ Harish A. "WWE Star Great Khali's Growth-Inducing Tumor Removed". ABC News. Archived from the original on 4 March 2016.
  37. ^ Oliver G. "The French Angel was more man than monster". SLAM! Wrestling. Archived from the original on 6 July 2015.
  38. ^ Login IS, Login J (July 2008). "Governor Pio Pico, the monster of California...no more: lessons in neuroendocrinology". Pituitary. 13 (1): 80–6. doi:10.1007/s11102-008-0127-1. PMC 2807602. PMID 18597174.
  39. ^ Nawar RN, AbdelMannan D, Selman WR, Arafah BM (2008). "Pituitary tumor apoplexy: a review". Journal of Intensive Care Medicine. 23 (2): 75–90. doi:10.1177/0885066607312992. PMID 18372348. S2CID 34782106.
  40. ^ Plaskin G (13 August 2013). "Playboy Interview: Tony Robbins". Playboy. Archived from the original on 2 April 2015. Retrieved 5 March 2015.
  41. ^ "Ex-treinador de Pezão, André Benkei explica doença do lutador e afirma: 'Ele jamais colocaria a saúde em risco'". 23 December 2013.
  42. ^ "TRT ban forces UFC headliner 'Bigfoot' Silva into surgery". 12 September 2014.
  43. ^ "UFC title hopeful 'Bigfoot' Silva a real-life giant". USA Today.
  44. ^ McLellan, Dennis (27 December 1992). "Shedding Light on a Rare Disease: Woman Hopes O.C. Group Will Increase Awareness of Life-Threatening Effects of Excessive-Growth Illness". Los Angeles Times.
  45. ^ Lippi, Donatella; Phillipe Charlier; Paola Romagnani (May 2017). "Acromegaly in Lorenzo the Magnificent, father of the Renaissance". The Lancet. 389 (10084): 2104. doi:10.1016/S0140-6736(17)31339-9. PMID 28561004. S2CID 38097951.
  46. ^ Ramachandran, Manoj; Jeffrey K Aronson (October 2006). "The diagnosis of art: Rachmaninov's hand span". Journal of the Royal Society of Medicine. 99 (10): 529–30. doi:10.1177/014107680609901015. PMC 1592053. PMID 17066567.
  47. ^ "Misbehaving Pituitaries". Damn Interesting. Retrieved 16 August 2024.
  48. ^ "Dutch Acromegaly Patient Marjon van Iwaarden Shares Her Story". Acromegaly Support - Rare Disease Awareness, Education, and Support. 27 May 2020. Retrieved 16 August 2024.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Acromegaly&oldid=1259911054"